{
    "name": "gadoterate meglumine",
    "comment": "Rx",
    "other_names": [
        "Dotarem",
        "Clariscan"
    ],
    "classes": [
        "Diagnostic Imaging Agents",
        "Gadolinium-Containing Contrast Agents"
    ],
    "source": "https://reference.medscape.com/drug/dotarem-gadoterate-meglumine-999823",
    "pregnancy": {
        "common": [
            "GBCAs cross the placenta and result in fetal exposure and gadolinium retention",
            "Human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive",
            "Estimated background risk of major birth defects and miscarriage for the indicated population is unknown",
            "All pregnancies have a background risk of birth defect, loss, or other adverse outcomes"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Estimated infant exposure is 0.001%-0.04% of the maternal dose",
            "Unknown whether the effects of the drug on the breastfed infant or the effects of the drug on milk production",
            "Developmental and health benefits of breastfeeding should be considered together with the motherâ€™s clinical need for the drug and any potential adverse effects on the breastfed infant or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Gadolinium-based contrast agents (GBCAs) increase risk of nephrogenic systemic fibrosis (NSF) among patients with impaired elimination",
                "Avoid use in these patients unless the diagnostic information is essential and not available with noncontrasted MRI or other modalities",
                "NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs",
                "Risk of NSF highest with chronic, severe kidney disease (ie, GFR <30 mL/min/1.73 m2) or acute kidney injury",
                "Screen for acute kidney injury and other conditions that may reduce renal function; for patients at risk for chronically reduced renal function (eg, age >60 years, hypertension, diabetes), estimate GFR through laboratory testing",
                "For patients at highest risk for NSF, do not exceed recommended dose and allow sufficient period of time for elimination of the drug before readministration"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "1.5"
        },
        {
            "name": "pediatric",
            "percent": "0.6"
        },
        {
            "name": "Nausea",
            "percent": "0.5"
        },
        {
            "name": "Headache",
            "percent": "0.4"
        },
        {
            "name": "adult",
            "percent": "0.2"
        },
        {
            "name": "Injection site pain",
            "percent": "0.2"
        },
        {
            "name": "Injection site coldness",
            "percent": "0.2"
        },
        {
            "name": "Burning sensation",
            "percent": "0.2"
        },
        {
            "name": "Feeling cold",
            "percent": "0.2"
        },
        {
            "name": "Rash",
            "percent": "0.2"
        },
        {
            "name": "Somnolence",
            "percent": "0.2"
        },
        {
            "name": "Fatigue",
            "percent": "0.2"
        },
        {
            "name": "Dizziness",
            "percent": "0.2"
        },
        {
            "name": "Vomiting",
            "percent": "0.2"
        },
        {
            "name": "Pruritus",
            "percent": "0.2"
        },
        {
            "name": "Asthenia",
            "percent": "0.2"
        },
        {
            "name": "Paraesthesia",
            "percent": "0.2"
        },
        {
            "name": "Dysgeusia",
            "percent": "0.2"
        },
        {
            "name": "Pain in extremity",
            "percent": "0.2"
        },
        {
            "name": "Anxiety",
            "percent": "0.2"
        },
        {
            "name": "Hypertension",
            "percent": "0.2"
        },
        {
            "name": "Palpitations",
            "percent": "0.2"
        },
        {
            "name": "Oropharyngeal discomfort",
            "percent": null
        },
        {
            "name": "Serum creatinine increased",
            "percent": null
        },
        {
            "name": "Injection site reactions",
            "percent": null
        },
        {
            "name": "including site inflammation",
            "percent": null
        },
        {
            "name": "extravasation",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "and warmth",
            "percent": null
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Bradycardia",
            "percent": null
        },
        {
            "name": "tachycardia",
            "percent": null
        },
        {
            "name": "arrhythmia",
            "percent": null
        },
        {
            "name": "hypotension",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Coma",
            "percent": null
        },
        {
            "name": "convulsion",
            "percent": null
        },
        {
            "name": "syncope",
            "percent": null
        },
        {
            "name": "presyncope",
            "percent": null
        },
        {
            "name": "parosmia",
            "percent": null
        },
        {
            "name": "tremor",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective tissue disorders",
            "percent": null
        },
        {
            "name": "Muscle contracture",
            "percent": null
        },
        {
            "name": "muscle weakness",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "salivary hypersecretion",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Malaise",
            "percent": null
        },
        {
            "name": "fever",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Nephrogenic systemic fibrosis",
            "percent": null
        },
        {
            "name": "Vascular disorders",
            "percent": null
        },
        {
            "name": "Superficial phlebitis",
            "percent": null
        }
    ]
}